PTC Therapeutics Q3 2023 EPS $(1.76) Misses $(1.17) Estimate, Sales $196.58M Miss $210.19M Estimate
Portfolio Pulse from totan@benzinga.com
PTC Therapeutics reported Q3 2023 earnings per share (EPS) of $(1.76), missing the analyst consensus estimate of $(1.17) by 50.43%. This is a 15.03% decrease from the same period last year. The company also reported quarterly sales of $196.58 million, missing the analyst consensus estimate of $210.19 million by 6.48%, a 9.46% decrease from the same period last year.
October 26, 2023 | 8:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PTC Therapeutics reported lower than expected Q3 2023 earnings and sales, which could negatively impact the stock price in the short term.
PTC Therapeutics reported lower than expected earnings and sales for Q3 2023. This miss on both fronts could lead to a decrease in investor confidence and a potential drop in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100